Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

23.89
+0.50502.16%
Post-market: 23.890.00000.00%16:10 EDT
Volume:2.04M
Turnover:48.89M
Market Cap:2.99B
PE:110.88
High:24.18
Open:23.63
Low:23.55
Close:23.38
52wk High:31.77
52wk Low:16.57
Shares:125.07M
Float Shares:111.18M
Volume Ratio:0.90
T/O Rate:1.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:13.54
PE(LYR):-188.28

Loading ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 15

MBX Biosciences Names Steve Hoerter CEO, Replacing Kent Hawryluk

Reuters
·
Jul 14

Arcutis Biotherapeutics (ARQT) Receives a Buy from Jefferies

TIPRANKS
·
Jul 09

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Seres Therapeutics (MCRB)

TIPRANKS
·
Jul 09

Arcutis Biotherapeutics Says FDA Accepted ZORYVE Expansion Filing for Infants With Eczema

MT Newswires Live
·
Jul 08

Arcutis Biotherapeutics announces FDA acceptance of Zoryve sNDA

TIPRANKS
·
Jul 08

FDA Accepts Arcutis Snda for Zoryve Cream Use in Infants with Atopic Dermatitis

Reuters
·
Jul 08

Arcutis Biotherapeutics - FDA Sets Pdufa Target Action Date of February 23, 2027 for Zoryve Cream 0.05% Snda

THOMSON REUTERS
·
Jul 08

FDA Accepts Supplemental New Drug Application for Arcutis’ Zoryve® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

THOMSON REUTERS
·
Jul 08

Arcutis Grants 61,000 Rsus to Nine New Hires Under 2022 Inducement Plan

Reuters
·
Jul 03

Arcutis Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 03

Arcutis Biotherapeutics - Launches Virtual Health Platform to Expand Access to Zoryve Portfolio

THOMSON REUTERS
·
Jun 30

Arcutis Biotherapeutics Wins FDA Approval For Expanded Pediatric Skin Drug Use

MT Newswires Live
·
Jun 30

FDA approves supplemental NDA to expand indication of Arcutis’ Zoryve cream

TIPRANKS
·
Jun 30

Arcutis Says FDA Approves Zoryve Cream for Plaque Psoriasis in Children as Young as 2

Reuters
·
Jun 30

FDA Approves Arcutis’ Zoryve® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

THOMSON REUTERS
·
Jun 30

Arcutis Biotherapeutics director Howard G. Welgus disposes of 4,731 common shares for $115,957.48

Reuters
·
Jun 18

Arcutis Stockholders Approve Proposals at 2026 Meeting

TIPRANKS
·
Jun 10

Arcutis Biotherapeutics shareholders elect Class III directors at annual meeting

Reuters
·
Jun 10

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 06